paraplegia

[키워드] acute respiratory syndrome Adults affected analysed antibody AstraZeneca attack available data AZD1222 blindness BNT162b2 booster vaccination Brain Brainstem Brainstem encephalitis Case report cerebrospinal fluid ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1-S CNS complete recovery coronavirus Coronavirus disease 2019 Coronavirus disease 2019 (COVID-2019) COVID-19 CSF detectable disease dysfunction Encephalitis epidemiological Escalation exceeded female first dose functional glycoprotein IgG1 immunization Immunoglobulin Immunotherapy laboratory feature Longitudinally extensive transverse myelitis (LETM) majority male median median age median interval MOG MOG antibodies (MOG-IgG) mRNA vaccine mRNA-1273 much lower Myelin Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) Myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis (MOG-EM) Myelitis Neuromyelitis Optica Neuromyelitis optica spectrum disorders occur occurred Optic Optic neuritis Oxford paraplegia Patient patients patients with SARS-CoV-2 Pfizer phenotype plasma Postinfectious Postvaccinal predominant radiological remained required residual symptom SARS-CoV2 serum Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) severity steroid treatment therapy Treatment Treatment outcome vaccination Vaccine WCC white cell
[DOI] 10.1007/s00415-022-11194-9 PMC 바로가기